ArticleMicrosystems & nanoengineering2025
Integrated individually addressable microneedle arrays for robust glucose monitoring and on-demand insulin releasing.
Article in Microsystems & nanoengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Next-generation microneedle patches for transdermal therapeutics and diagnostics.Discover nano · 2026Review
- Bioelectronic Considerations in Biomedical Microneedles.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Beyond Detection Limits: Integrated Biosensors for Molecular Diagnostics, Longitudinal Monitoring, and Clinical Translation.Biosensors · 2026Review
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Highly cited original research in microneedle science from 2015 to 2025 a bibliometric and altmetric analysis.Discover nano · 2026Review
- Smart microdevices for biomedical drug delivery: endogenous stimuli as the key to safer therapeutics.RSC advances · 2026Review
- Integrating Polymeric 3D-Printed Microneedles with Wearable Devices: Toward Smart and Personalized Healthcare Solutions.Polymers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-time glucose monitoring and adaptive insulin administration are critical for effective diabetes management. Minimally invasive microneedle-based glucose monitoring sensors offer a promising approach but suffer from signal drift due to tissue reactions, inconsistent implantation, or mechanical damage to their sensitive layers during insertion. Moreover, microneedle-based insulin delivery faces limitations in achieving accurate and quantitatively controlled release due to its passive response mechanism. Here, we report a minimally invasive platform integrating a multiplexed glucose biosensor array with on-demand insulin delivery for precise glycemic control. To prevent the impact of potential individual microneedle failure post-insertion, the system incorporates a redundant sensing array comprising four individually addressable electrodes functionalized with glucose oxidase, providing robust and reliable glucose measurements. Simultaneously, an addressable drug-release array of eight microneedles loaded with insulin within redox-responsive hydrogels enables localized electrochemical triggering for spatiotemporally controlled insulin release. These components are coordinated via a wireless interface leveraging real-time multi-channel ADC data processing and Bluetooth transmission to dynamically activate insulin microneedles based on algorithmic glycemic thresholds. The platform's redundant sensing design enhances system reliability, maintaining accurate glucose monitoring even in case of individual sensor failure, while its on-demand insulin release enables real-time glycemic regulation. Ultimately, in vivo experiments in rats were conducted to verify the system's efficacy. By synergizing multiplexed biosensing, fault tolerance, and programmable drug delivery, this platform addresses critical limitations of current glucose monitoring systems and establishes a demonstration prototype for next-generation closed-loop bioelectronics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.